Change in Serum Lactate Dehydrogenase Is Associated with Outcome of Patients with Advanced-stage NSCLC Treated with Erlotinib
Jazyk angličtina Země Řecko Médium print
Typ dokumentu časopisecké články
PubMed
27127158
PII: 36/5/2459
Knihovny.cz E-zdroje
- Klíčová slova
- EGFR-TKI, LDH, Lactate dehydrogenase, NSCLC, biomarker, erlotinib, lung cancer, prediction,
- MeSH
- dospělí MeSH
- erlotinib terapeutické užití MeSH
- L-laktátdehydrogenasa krev MeSH
- lidé středního věku MeSH
- lidé MeSH
- nádory plic krev farmakoterapie MeSH
- nemalobuněčný karcinom plic krev farmakoterapie MeSH
- protinádorové látky terapeutické užití MeSH
- retrospektivní studie MeSH
- senioři nad 80 let MeSH
- senioři MeSH
- výsledek terapie MeSH
- Check Tag
- dospělí MeSH
- lidé středního věku MeSH
- lidé MeSH
- mužské pohlaví MeSH
- senioři nad 80 let MeSH
- senioři MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- Názvy látek
- erlotinib MeSH
- L-laktátdehydrogenasa MeSH
- protinádorové látky MeSH
BACKGROUND: Serum lactate dehydrogenase (LDH) has been reported as a prognostic biomarker in malignant diseases. However, little is known on the dynamics of serum LDH levels during systemic treatment. We focused on the association of changes in serum LDH with outcome of patients with advanced-stage non-small cell lung cancer (NSCLC) treated with erlotinib. PATIENTS AND METHODS: Clinical data of 309 patients were analyzed. Serum samples were collected within one week before initiation and after one month of treatment. RESULTS: The change in serum LDH during the first month of erlotinib treatment was independently associated with disease control rate (p=0.006), progression-free survival (PFS) (p=0.010) and overall survival (OS) (p<0.001). CONCLUSION: LDH is a commonly used serum biomarker, that is cheap and easy to detect. The results of our study suggest that the change in LDH serum level during the first month is a surrogate marker on the efficacy of erlotinib in patients with advanced NSCLC.
Center for Applied Genomics of Solid Tumours Genomac Research Institute Prague Czech Republic
Institute of Biostatistics and Analysis Faculty of Medicine Masaryk University Brno Czech Republic
